Cephalon, Teva Settle Patent Dispute Over Provigil

Law360, New York (December 11, 2005, 12:00 AM EST) -- Cephalon Inc. and Israeli generic-drug maker Teva Pharmaceutical Industries Ltd. have struck a deal to put an end to their patent disputes involving Cephalon's narcolepsy drug Provigil, the two companies said.

Under the terms of the settlement, Cephalon will grant Teva the rights to market its generic version of Provigil in the U.S. up to three years before Cephalon's patent expires in October 2014, or as early as October 2011, the companies said.

In return, Teva will pay for royalties to Cephalon generated from any generic-drug...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.